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Abstract
High affinity, gamma-aminobutyric acid (GABA) plasma membrane transporters (GATs) influence the availability
of GABA, the main inhibitory neurotransmitter in the brain. Recent studies suggest a crucial role for GATs in
maintaining levels of synaptic GABA in normal as well as abnormal (i.e., epileptic) adult brain. However, the role of
GATs during development and specifically changes in their expression in response to developmental seizures are
unknown. The present study examined GAT-1-immunolabeling in infant rats with two types of developmental
seizures, one induced by corticotropin-releasing hormone (CRH) lasting about 2 h and the other by hyperthermia (a
model of febrile seizures) lasting only 20 min. The number of GAT-1-immunoreactive (ir) neurons was increased in
several forebrain regions 24 h after induction of seizures by CRH as compared to the control group. Increased
numbers of detectable GAT-1-ir cell bodies were found in the hippocampal formation including the dentate gyrus and
CA1, and in the neocortex, piriform cortex and amygdala. In contrast, hyperthermia-induced seizures did not cause
significant changes in the number of detectable GAT-1-ir somata. The increase in GAT-1-ir somata in the CRH
model and not in the hyperthermia model may reflect the difference in the duration of seizures. The brain regions
where this increase occurs correlate with the occurrence of argyrophyllic neurons in the CRH model. © 2000 Elsevier
Science B.V. All rights reserved.
Keywords: GABA transporter; Corticotropin-releasing hormone; Febrile seizures; Infant rat
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1. Introduction
The majority of seizures occurring in the devel-
oping human are not spontaneous; i.e., they are
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not related to inherent abnormalities in the bal-
ance of neuronal excitation and inhibition. In-
stead, most developmental seizures are provoked
by injurious or stressful stimuli (Baram and
Hatalski, 1998). Thus, seizures during develop-
ment may be induced by hypoxia (Jensen et al.,
1998) or fever (see Baram et al., 1997b for re-
view). Febrile seizures represent an important
type of developmental seizure. They are ex-
tremely common in the human and have been
modeled in the immature rat (Baram et al.,
1997b; Toth et al., 1998; Chen et al., 1999;
Dube et al., 2157). The mechanisms by which
these stressful stimuli cause seizures are not
clear. However, recently a role for the stress-ac-
tivated excitatory neuropeptide, corticotropin-re-
leasing hormone (CRH)(Vale et al., 1981), has
been suggested in developmental seizures (Baram
and Hatalski, 1998). Stress activates the expres-
sion of CRH in several brain regions that are
involved in the circuitry for stressful stimuli
(Hatalski et al., 1998). The limbic system, par-
ticularly the amygdala and hippocampus, is rich
in neuronal populations that either synthesize
CRH or possess CRH receptors (Swanson et al.,
1983; De Souza et al., 1985; Avishai-Eliner et
al., 1996). CRH functions as an excitatory neu-
romodulator (Aldenhoff et al., 1983; Ehlers et
al., 1983; Hollrigel et al., 1998). In fact, picomo-
lar amounts of CRH induce severe and pro-
longed seizures within minutes in young rats
(Baram and Schultz, 1991; Baram et al., 1992;
Baram and Schultz, 1995). Furthermore, re-
peated administration of CRH doses (150 
1012 mole), which results in status epilepticus,
leads to enhanced excitability of the limbic cir-
cuit (Baram and Hatalski, 1998) and to excito-
toxic injury in select hippocampal and amygdala
neurons in the infant rat (Baram and Ribak,
1995; Ribak and Baram, 1996). This informa-
tion suggests that some stressors (i.e., hypoxia
and hyperthermia) may provoke seizures early in
life by increasing the levels of CRH in limbic
structures. CRH-induced seizures are a model of
developmental seizures because they are far
more robust during the second posnatal week in
rats than in adults (Baram et al., 1992; Baram
and Hatalski, 1998). This may be partially
due to high levels of the CRH receptor in lim-
bic regions at this time (Avishai-Eliner et al.,
1996).
Many previous neurophysiological studies
have indicated that a failure of inhibition is a
principal reason for neuronal hyperexcitability
during epileptic seizures (Gean et al., 1989;
Kamphuis et al., 1987; Kapur et al., 1989; Mo-
rimoto et al., 1987a,b; Ribak, 1991). Gamma-
aminobutyric acid (GABA) is the major
inhibitory neurotransmitter in the central ner-
vous system. Extracellular GABA concentrations
in the synaptic cleft are regulated by the activity
of GABAergic neurons and by specific Na de-
pendent transporter proteins on presynaptic ter-
minals and glial cells involved in GABA uptake
(Iversen and Kelly, 1975). Molecular studies
have revealed at least four subtypes of GABA
transporters: GAT-1, GAT-2, GAT-3 and BGT-
1 (Borden et al., 1992; Guastella et al., 1990;
Clark et al., 1992). These transporters have sev-
eral possible functional roles, including the inac-
tivation of GABA’s action in synaptic
transmission by removing GABA from the
vicinity of its receptors (Iversen and Kelly, 1975;
Schousboe, 1981; Isaacson et al., 1993).
GAT-1 has been demonstrated within neurons
and astrocytes in various regions of the rat
brain, including the olfactory bulb, neocortex,
hippocampus, ventral pallidum and cerebellum
(Durkin et al., 1995; Minelli et al., 1995; Ribak
et al., 1996). The neuronal localization of GAT-
1 in the adult hippocampus is exclusively within
axon terminals forming symmetric synapses, in-
cluding those from GABAergic basket and
chandelier cells (Ribak et al., 1978, 1996). In
young rats at 10–30 postnatal days (PND) of
age, GAT-1 is also localized to the somata and
dendrites of GABAergic interneurons in the
neocortex and hippocampus (Yan et al., 1997).
The number of labeled somata varied with the
age of the rat during this period. A role for
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GATs in adult seizures has been established
(Akbar et al., 1998; During et al., 1995; Hirao
et al., 1998; Mathern et al., 1999). Here we
tested the hypothesis that seizures influence the
normal distribution of GAT-1-immunolabeling
in the immature brain. Thus, the present study
addresses the question of whether an alteration
in transporter distribution occurred after two
types of developmental seizures: CRH-induced
and hyperthermia-induced seizures. Immunocyto-
chemical techniques were used to assess regional
differences in the number of GAT-1 labeled
neurons in rats with both types of seizure, and
those data were compared to that of vehicle-
treated controls.
2. Materials and methods
2.1. Animals
Rats were the offspring of time-pregnant,
Sprague-Dawley dams. Rats were born in our
federally approved animal facility and were kept
on a 12 h light:dark cycle. The time of birth of
the pups were determined every 12 h, and the
day of birth was considered day 0. Litters were
culled to 12 pups and mixed among experimen-
tal groups. Cages were maintained in a quiet
room, and were undisturbed for 24 h prior to
experiments.
2.2. CRH-infusions
Pups [10 postnatal days of age (PND)] were
implanted with cannulae 24 h prior to experi-
ments, and the position of the cannulae was ver-
ified histologically in all cases (see below).
Briefly, stainless steel cannulae were implanted
into the lateral ventricles under halothane anes-
thesia, using an infant rat stereotaxic apparatus
as described elsewhere (Baram et al., 1992,
1997a; Baram and Schultz, 1995; Brunson et al.,
1998). Infant rats (n  9) were injected once
with CRH i.c.v. on 11 PND. The infusions were
made while the pups were freely moving in a
heated Plexiglas chamber. CRH (5 mg in 1 ml)
was infused via the chronic cannula using a mi-
cro-infusion pump. Cannula-carrying control an-
imals (n  7) were given a dye vehicle (Baram
et al., 1992, 1997a). Subsequent to CRH infu-
sion, seizure latency and duration were moni-
tored: animals were scored for behavioral limbic
seizures occurring within 5-min epochs (Baram
et al., 1997a; Baram and Schultz, 1995). The
concordance of limbic automatism and epileptic
discharges induced by CRH has been established
previously (Baram et al., 1992, 1997a).
2.3. Hyperthermia induction paradigm
The hyperthermic seizure paradigm has been
described previously (Baram et al., 1997b; Toth
et al., 1998; Dube et al., 2157). Briefly, the core
temperature of 5 pups (PND 10) was raised us-
ing a regulated stream of moderately heated air.
Pups were placed on the floor of a 3 l glass
container and the air stream was directed :50
cm above them. Rectal temperatures were mea-
sured at baseline, at 2-min intervals, and at the
onset of hyperthermia-induced seizures. Hyper-
thermia was maintained for 30 min, aiming for
a core temperature of 41°C, and the presence
and duration of seizures for each pup were
noted at 2-min intervals. After the hyperthermic
period, rats were placed on a cool surface, mon-
itored for 15 min, and then returned to their
home cages for rehydration by the mothers. The
behavioral seizures in this paradigm are stereo-
typed and easily monitored. They were previ-
ously shown to correlate with EEG rhythmic
epileptiform discharges from the hippocampus
and amygdala (Baram et al., 1997b; Dube et al.,
2000). These seizures consist of complete arrest
of the heat-induced hyperkinesis, unilateral body
flexion and biting of an extremity, occasionally
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followed by clonic or swimming motions. Another
group of rats (n  4) received pentobarbital (PB)
(30 mg:kg) just before induction of hyperthermia.
2.4. Tissue preparation
At 4 h (n  3) or 24 h (n  6) following CRH
treatment and at 24 h following hyperthermia the
experimental and age-matched control groups
were anesthetized with sodium pentobarbital and
perfused transcardially with 0.12 M phosphate
buffered saline (PBS, pH 7.4) followed by 4%
paraformaldehyde and 0.2% glutaraldehyde in
phosphate buffer (pH 7.4). Brains were then
removed from the rats, placed in fixative for 24 h
at 4°C, and transferred to cold PBS for several
hours to a few days. The brains were sectioned in
the coronal plane at 60 mm with a vibratome.
Sections through both hemispheres, including
those at the injection site, were collected in
tissue-culture wells in cold PBS.
2.5. Immunocytochemistry
Free-floating sections from both control and
experimental animals were immunostained for
GAT-1 using a standard avidin-biotin complex
(ABC) method. Sections were processed simulta-
neously using the same reagents and incubation
times. Endogenous peroxidase activity was
blocked with a 20-min incubation in 0.1% H2O2.
Then, the sections were incubated in 5% normal
horse serum (NHS) at room temperature for 2
h. Sections were then placed in a PBS solution
containing 5% NHS, 0.5% Triton X-100 and
rabbit anti-GAT-1 serum (1:2500) at 4°C for 48
h. After several rinses with PBS containing 0.1%
Triton X-100, sections were incubated in 1%
anti-rabbit IgG with 5% NHS for 2 h at room
temperature. Then, sections were rinsed again
and incubated in 1% ABC solution for 1 h. Af-
ter several rinses in PBS, bound antibody was
visualized by incubating sections in 0.05% DAB
and 0.005% H2O2. Sections were mounted on
gelatin-subbed slides and allowed to air-dry for
at least 30 min. Then, sections were dehydrated
in ascending ethanols, cleared in xylene and cov-
erslips were applied with DPX mounting
medium.
2.6. Quantitati6e analysis
Sections from the dorsal hippocampus were
used for counting immunoreactive neurons in
the hippocampal formation. The number of cells
in each hippocampal subregion was expressed as
the mean number of immunoreactive cells per
section, after manual counting at a magnifica-
tion of 200 with the aid of an ocular grid
(Pitkanen et al., 1999). Sections were divided
into equivalent septotemporal levels, between 2.0
and 2.3 mm rostral to Bregma (Sherwood and
Timiras, 1970). Five to 10 sections from these
levels were counted for each rat, and only sec-
tions with consistent immunostaining were used.
Immunoreactive neurons were counted in all
parts of the hippocampus and dentate gyrus.
The number of GAT-1-ir somata in the
neocortex, piriform cortex and amygdala was
expressed as the number of GAT-1-ir cell bodies
per unit area. A grid reticule of 100 frames cov-
ering an area of 250  250 mm2 was centered
over the parietal cortex to obtain data for the
neocortex and between the dorsal endopiriform
nucleus and ventral endopiriform cortex for the
piriform cortex. A similar method was used to
count GAT-1-ir somata in the basal amygdala
nucleus.
2.7. Statistical analysis
Data were obtained from both hemispheres.
Results were analyzed for statistical significance
(P B 0.05) using a one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison
posthoc test (Sigma Stat Program; Jandel Scien-
tific, USA). The number of GAT-1-ir somata in
the experimental groups was also expressed as a
percentage of the control group.
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3. Results
3.1. Distribution and localization of
GAT-1-immunoreacti6ity in the control group
3.1.1. Hippocampal formation
The regional immunolabeling pattern for
GAT-1 in control brains was similar to that de-
scribed previously for the hippocampal forma-
tion and neocortex in young rats (Yan et al.,
1997). GAT-1-immunoreactivity (ir) in the den-
tate gyrus was dense in the molecular layer and
lighter in the hilus where mainly unlabeled
mossy fibers were found. The somata of unla-
beled hippocampal principal neurons, granule
and pyramidal cells, were outlined by small im-
munolabeled puncta (Fig. 1A and C, Fig. 2A
and B). The CA3 area showed lighter GAT-1-ir
Fig. 1. Photomicrographs of GAT-1-ir in the rat hippocampus. (A) and (B): Low magnifications of the control group (A) and the
24 h CRH group (B). Note the intense GAT-1-ir in the supragranular layer of the dentate gyrus (DG) and pyramidal cell layer
(CA3, CA1). (C) and (D) show details of GAT-1-ir puncta and somata in the dentate gyrus. (C): Control group and (D): The 24
h CRH group show several immunopositive somata (arrows) within or close to the granule cell layer. Note that many more are
shown in (D) than in (C). GL; granule cell layer, ML; molecular layer, H; hilus and SUB; subiculum. Scale bars  100 mm in (A)
and (B); 20 mm in (C) and (D).
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Fig. 2. Details of GAT-1-ir puncta and somata in several regions of the hippocampal formation. (A–C): Control group. Numerous
puncta and fibers are shown in CA3 (A), CA1 (B) and the subiculum (C) and some unlabeled somata (arrows). (D–F): The 24 h
CRH group. Several immunopositive somata (arrows) are in strata pyramidale, lucidum and radiatum in CA3 (D) and CA1 (E).
They have the features of interneurons (see text). (F) Numerous GAT-1-ir somata (arrows) appear in the subiculum. O; stratum
oriens, R; stratum radiatum; L; stratum lucidum, PL; stratum pyramidale. Scale bar  20 mm.
in stratum lucidum, the termination zone of
mossy fibers. In contrast, strata radiatum and
lacunosum-moleculare of CA3 displayed denser
GAT-1-ir (Fig. 1A). The strata oriens, lucidum
and radiatum showed a few GAT-1-ir cell bodies
(Fig. 2A). The CA1 area showed lighter GAT-1-ir
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in stratum pyramidale as compared to CA3 (cf.,
Fig. 2A and B). Some fusiform GAT-1-ir cell
bodies were found in stratum pyrami- dale. The
subiculum showed a similar GAT-1 labeling pat-
tern to that found in CA1 in that the somata of
unlabeled pyramidal cells were outlined by small
immunolabeled puncta. However, GAT-1-ir cell
bodies were absent in the subiculum (Fig. 2C).
3.1.2. Neocortex
The pattern of GAT-1-ir in the neocortex was
similar in all sections examined and consisted of
labeled punctate structures, radially or obliquely
oriented fibers and somata (Fig. 3A and Fig. 4B).
GAT-1-ir puncta were relatively sparse in layer I.
In the other layers, GAT-1-ir appeared to be
distributed homogeneously, although it was
slightly increased in layer IV and the supragranu-
lar layers (Fig. 3A). In layers II–VI, numerous
GAT-1-ir puncta outlined the somata and proxi-
mal dendrites of pyramidal and nonpyramidal
cells (Fig. 4A). Small, round or oval GAT-1-ir
somata were found in all cortical layers but
mostly in layers IV and VI (Fig. 4B). GAT-1-ir
fibers were also observed in the underlying white
matter.
Fig. 3. GAT-1-ir in the neocortex. (A): Control group. (B): The 4 h CRH group is similar to the control group. (C): The 24 h CRH
group shows several more GAT-1-ir somata (arrows) throughout the cortex than in either (A) or (B). Layers are indicated by Roman
numerals I–VI. Scale bar  100 mm.
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Fig. 4. Details of GAT-1-ir puncta and somata in the rat neocortex. In all panels (A–F), GAT-1-ir puncta are apposed to the
somata and proximal dendrites of unlabelled pyramidal neurons (asterisks). (A) and (B): The control group showed some GAT-1-ir
somata in layers II and VI, respectively. (C) and (D): The 4 h CRH group also showed some GAT-1-ir somata in the same respective
layers. (E) and (F): The 24 h CRH group shows several more GAT-1-ir somata (arrows) and the quantitative data indicated a
significant increase. Layer II in panels (A), (C) and (E); Layer VI in panels (B), (D) and (F). Scale bar  10 mm.
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Fig. 5. Histograms of the number of GAT-1-ir somata in the examined subfields of the hippocampal formation (mean 9 S.D.)
compared to the control group in each hemisphere (one-way ANOVA with Bonferroni’s posthoc test) *P B 0.002, **P B 0.05 and
cP B 0.001.
Fig. 6. Histograms of the number of GAT-1-ir somata in some of the strata of the hippocampal formation and the subiculum
(mean 9 S.D.) as compared to the control group in each hemisphere (one-way ANOVA with Bonferroni’s posthoc test)
**P B 0.05.
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3.2. Effects of CRH-induced seizures on the
distribution of GAT-1-ir
3.2.1. Hippocampal formation
Increased numbers of detectable GAT-1-ir cell
bodies and more intensely labeled puncta were
found throughout the hippocampal formation in
rats examined 24 h after CRH-induced seizures
compared with controls. In the dentate gyrus,
GAT-1-ir puncta were more concentrated in the
granule cell layer and hilus than in those struc-
tures in control rats (cf., Fig. 1B and D). Nu-
mer-ous round and fusiform GAT-1-ir cell
bodies were located in the lower border of the
granule cell layer (Fig. 1D) and were probably
basket cells (Ribak and Seress, 1983). The num-
ber of detectable GAT-1-ir cell bodies in the
granule cell layer of the dentate gyrus was sig-
nificantly increased in both hemispheres; (P B
0.002) in the ipsilateral side and (P B 0.001) in
the contralateral side as compared to the control
group (Fig. 5). Significantly increased numbers
of immunolabeled somata were also observed in
the hilus (P B 0.05) of the ipsilateral hemi-
sphere as compared to the control group (Fig.
5). More immunoreactive neurons were found in
the rostral sections than in the caudal ones, and
this variation could arise from a delayed devel-
opment of the caudal hippocampus (Bayer,
1980).
A normal pattern of GAT-1-ir puncta with
vertically oriented rows of boutons was found in
Ammon’s horn (Fig. 2D). Numerous GAT-1-ir
cell bodies were also observed, but their number
in CA3 was not significantly different than that
of the control group for both sides (Fig. 5).
However, the number of detectable GAT-1-ir
cells in stratum pyramidale of CA1 was signifi-
cantly increased on both the ipsilateral (P B
0.002) and contralateral (P B 0.001) sides as
compared to the control group (Fig. 5). The
GAT-1-ir cell bodies were also counted in strata
lucidum, oriens and lacunosum-moleculare but
no significant dif-ferences were found (Fig. 6).
These latter im-munolabeled somata were mostly
small and round (Fig. 2D and E).
GAT-1-ir puncta in the subiculum from the
24 h CRH group were present around unlabeled
pyramidal cells and appeared similar to the con-
trol group (cf., Fig. 2 C and F). However, the
former preparations also showed numerous
GAT-1-ir somata (Fig. 2F) while the control
group had none. These round and fusiform im-
munolabeled cells were smaller than pyramidal
cells indicating that they were probably in-
terneurons (Swanson et al., 1987). The quantita-
tive data indicated a highly significant increase
in the number of detectable GAT-1-ir somata in
the 24 h group as compared to the control
group (Fig. 6).
Fig. 7. Histograms of the number of GAT-1-ir somata in the
cerebral cortex (neocortex), piriform cortex and amygdala
(mean 9 S.D.) as compared to the control group in each
hemisphere (one-way ANOVA) cP B 0.001.
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Fig. 8. Photomicrographs of piriform cortex. (A): Low magnification of the control group. (C): Details of the GAT-1-ir puncta and
GAT-1-ir negative somata (asterisks) and their dendrites in layers II and III from the left side of panel (A). (B): Low magnification
of the 24 h CRH group that shows numerous GAT-1-ir somata (arrows) in all layers. (D): Enlargement of the GAT-1-ir somata
(arrows) from the center of panel (B). Pir, piriform cortex. Scale bar  100 mm (A and B) and 20 mm (C and D).
Findings in the 4 h group were indistinguish-
able from those of controls throughout the
hippocampal formation. GAT-1-ir cell bodies
were present in all strata of the hippocampus and
dentate gyrus. The only region where the number
of immunolabeled cells was significantly increased
(P B 0.02) was in stratum pyramidale of CA1
(Fig. 5).
3.2.2. Neocortex
GAT-1-ir in the 24 h CRH-group was localized
throughout the layers and the underlying white
matter. GAT-1-ir puncta were found in all
neocortical layers and observed around the so-
mata of pyramidal cells and non-pyramidal cells
(Fig. 3C and Fig. 4E) as shown previously for
controls. Furthermore, all layers of neocortex had
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GAT-1-ir non-pyramidal cell bodies (Fig. 3C
and Fig. 4F). The immunolabeled somata were
of various sizes and shapes. The great majority
of the labeled somata were bipolar with small to
medium sizes (Fig. 4F). More labeled neuronal
somata were found in the 24 h CRH group
(Fig. 7) and statistical tests showed a significant
increase as compared to the control group (P B
0.001).
The 4 h CRH group showed the same distri-
bution pattern of GAT-1-ir puncta as that ob-
served in the control group (Fig. 3B and Fig.
4D). Also, some non-pyramidal cells were im-
munolabeled for GAT-1 but their number was
similar to that of the control group (P \ 0.05;
ANOVA).
3.2.3. Other forebrain regions
The previous study by Yan et al. (1997) de-
scribed GAT-1-immunolabeled somata in the
neocortex and hippocampus of young rats. Dur-
ing the course of the present study, numerous
GAT-1-ir somata were observed in other fore-
brain regions of the 24 h CRH group, specifi-
cally the piriform cortex and amygdala (Fig. 8B
and Fig. 9B). Only small numbers of immunola-
beled somata were found in the control group in
these brain regions (Fig. 8A and Fig. 9A). The
labeled somata in the 24 h CRH group were
found in the outer layers (layers II and III) of
the piriform cortex (Fig. 8B and D). These cells
were of vari-ous sizes and shapes. GAT-1-ir
puncta were also found around the somata and
dendrites of neurons in the piriform cortex simi-
lar to that in the neocortex, and the 24 h CRH
and control groups had similar distributions of
GAT-1-ir puncta (Fig. 8A–D). The 24 h group
also showed GAT-1-ir processes that were thick,
and extended from layer II into layer I near the
surface of the brain (Fig. 8D). Only a few such
processes were observed in the piriform region
from the control group (Fig. 5C). The number
of detectable GAT-1-ir cell bodies in piriform
cortex was significantly increased (P B 0.001) in
both hemispheres as compared to the control
group (Fig. 7).
GAT-1-ir puncta in the amygdala of the 24 h
CRH group resembled the distribution of that
present in the control group. However, numer-
ous small and round GAT-1-ir somata were
present in the 24 h group (Fig. 9B and D) while
the control group had only a few GAT-1-ir so-
mata (Fig. 9A and C). The number of GAT-1-ir
cells in the amygdala was significantly increased
(P B 0.001) in both hemispheres as compared
to the control group (Fig. 7).
Fig. 9. GAT-1-ir in the amygdala. (A): Low magnification of
the control group showing GAT-1-ir puncta and GAT-1-ir
somata (arrows). (C): Details of the morphology of GAT-1-ir
somata (arrow) and GAT-1-ir negative somata (asterisk). (B):
Low magnification of the 24 h CRH group and (D): an
enlargement to show the morphology of GAT-1-ir somata.
Note an increase in their number as compared to (C). Scale
bar  100 mm (A and B) and 20 mm (C and D).
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Fig. 10. Histograms of the number of GAT-1-ir somata in the dentate gyrus and hippocampal formation for both hyperthermic
groups (HT-hyperthermia-induced seizures and PB-pentobarbital treated rats prior to hyperthermia). The data represent mean 9
S.D. The results were analyzed for statistical significance (P B 0.05) using a one-way analysis of variance (ANOVA) and
Bonferroni’s multiple comparison posthoc test. The raw data were expressed as a percentage of the control group.
3.3. Effects of hyperthermia-induced seizures on
the distribution of GAT-1-ir
The regional labeling pattern for GAT-1-ir in
the neocortex and hippocampus was not influ-
enced by hyperthermic seizures or hyperthermia
alone (i.e., when seizures were eliminated with
PB). GAT-1-ir cell bodies occurred in all strata
of the hippocampus and dentate gyrus, and they
showed similar morphological features as those
in the control group. The number of detectable
GAT-1-ir somata did not vary significantly
among the three groups (Figs. 10 and 11). It
should also be noted that no immunolabeled so-
mata were observed in the subiculum.
4. Discussion
The results of this study indicate that GAT-1-
ir is altered by CRH-induced seizures but not
by hyperthermia or hyperthermia-induced
seizures. Changes induced by CRH seizures ap-
pear to depend on the time following CRH in-
fusion and are region specific. Our data showed
significant increases in the number of detectable
GAT-1-ir neuronal somata in specific forebrain
areas in the 24 h CRH group as compared to
the control group. However, the number of neu-
rons with GAT-1-ir was not altered in either the
4 h CRH group or hyperthermia-induced seizure
groups.
GAT-1 Immunolabeling of GABAergic Somata.
GAT-1-ir in control infant rats was found
within the cell bodies and dendrites of GABAer-
gic interneurons in the cerebral cortex. This
finding is consistent with the results of a previ-
ous study by Yan et al. (1997); showing that
GAT-1-ir appeared in the somata and dendrites
of 5-day old rats, but the rats 45 days old and
older had GAT-1-ir limited to axon terminals of
GABAergic neurons. These authors hypothe-
sized that the transient immunolabeling of
GABAergic interneurons for GAT-1 may be in-
volved in releasing GABA from somal and den-
dritic membranes through a non-vesicular
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mechanism during development as part of the
neurotrophic role of GABA in this period.
The data from the 24 h CRH group suggest
that the significant increase in the number of
detectable GAT-1-ir neurons in the hippocampal
formation, neocortex, piriform cortex and amyg-
dala reflects increased expression of GAT-1 by
GABAergic interneurons. First, labeled cells
were likely interneurons because the morphology
of the immunolabeled somata was nonpyrami-
dal. Second, the immunolabeled neurons in the
24 h CRH group were distributed in the laminar
location of GABAergic interneurons (Freund
and Buzsaki, 1996; Jones, 1993). Although gran-
ule cells in the dentate gyrus continue to be
generated at the age of rats in this study,
hippocampal interneurons are generated prior to
this age (Amaral and Kurz, 1985). Therefore,
the increase in the number of GAT-1-immunola-
beled neurons in the 24 h group is interpreted
as an increase in labeling of GABAergic in-
terneurons that are present in the brain at the
time of seizure induction.
What is the reason for the increased number
of detectable GAT-1-immunolabeled somata fol-
lowing CRH-induced seizures? An intriguing
possibil-ity is that the increase may provide the
basis for increased release of GABA via a non-
vesicular mechanism following the excitatory
surge caused by CRH-induced seizures (Baram
and Hatalski, 1998). Thus, the GAT-1-ir in-
crease and the proposed concommitant increase
in non-vesicular release of GABA may provide
a compensatory mechanism that may counteract
the hyperexcitability in the amygdala–hippocam-
pal limbic circuit following CRH-induced
seizures (Brunson et al., 1998). Induction of
GAT-1, at least at the level of protein expres-
sion, requires more than 4 h because it was not
observed in the 4 h group. Therefore, our study
indicates that CRH-induced seizures can trigger
increases in GAT-1 levels. Future studies are
needed to determine the persistence of this
change.
The present results also showed increased
numbers of detectable GAT-1-ir somata in piri-
form cortex and the basal nucleus of the amyg-
dala in the 24 h CRH group. Numerous
GAT-1-ir somata were observed in layers II and
III of piriform cortex as compared to only a
few in the control group. Also, the 24 h CRH
group had enlarged and more numerous GAT-1-
ir processes in this brain region. Some of these
processes were thick and could be dendrites. It
is conceivable that the increased expression of
Fig. 11. Histograms of the number of GAT-1-ir somata in
several strata of the hippocampal formation for both hyper-
thermic groups (HT and PB as defined in Fig. 10). The data
represent mean 9 S.D. The results were analyzed for statisti-
cal significance (P B 0.05) using one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison posthoc test.
The cell counts were expressed as a percentage of the control
group.
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GAT-1 may be a non-specific response to seizures
or stress. However, the remarkably selective dis-
tribution of the changes in GAT-1 levels indicates
that it correlates with brain areas that displayed
argyrophillic neurons in a previous study (Baram
and Ribak, 1995). It needs to be noted that the
basal nucleus of the amygdala was incorrectly
labeled in that paper. The fact that the number of
GAT-1 labeled somata was increased by CRH-in-
duced seizures but not by hyperthermia-induced
seizures indicates that it is not seizures per se (or
seizure-associated stress, per se) that determines
GAT-1 expression. A selective effect mediated by
activity of CRH receptors cannot be excluded
(Hatalski et al., 1998).
Hyperthermia-Induced Seizures. Febrile seizures
in the immature rat did not increase the number
of detectable GAT-1-ir somata in any forebrain
structure analyzed compared to controls. These
findings indicate that the hyperthermic seizure
model is different from the CRH model in regard
to the short-term response (24 h) of GABAergic
neurons. First, the lack of a change in the number
of detectable GAT-1-ir somata could be due to
the difference in the duration of seizures. CRH-in-
duced seizures last for about 2 h while those
induced by hyperthermia are only about 20 min in
length. Another basis for this difference comes
from the recent study by Chen et al. (1999) eluci-
dating the nature of the modulation of the
hippocampal circuit in the hyperthermia model.
Their in vitro studies revealed a selective increase
in inhibitory synaptic transmission in hippocam-
pal CA1 neurons (Chen et al., 1999). This finding
is consistent with increased GABA in the synaptic
cleft, and would not be expected to trigger mecha-
nisms for further enhancement of synaptic GABA
levels. In summary, GAT-1 protein expression in
the immature brain may be upregulated by devel-
opmental seizures. The specific determinants of
this upregulation remain to be delineated.
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